Friday, February 02, 2018 10:15 PM ET
Syros Pharmaceuticals (SYRS) Insider Makes Significant Share purchase Extending the Buying Trend over Last Quarter
There was a noteworthy insider buy in Syros Pharmaceuticals shares today as revealed in a filing with the SEC. One insider — Dr Srinivas Akkaraju, Director — acquired 209,424 shares in the company having a net market value of approximately $1,999,999. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been buys resulting in the acquisition of 124,774 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net purchases of 334,198 shares and have averaged 111,399 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at Syros Pharmaceuticals is higher than the 45-company peer group average. Biopharmaceuticals peer group saw 33 buy/sell trades during this period for an average of 0.7 transactions per company. The number of shares per buy/sell trade for Syros Pharmaceuticals insiders was also higher. Within the peer group there were 160,343 shares purchased and 1,029,573 shares sold with company insiders selling 26,340 shares on average.
The data used in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.